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Methicillin-resistant Staphylococcus aureus (MRSA) has recently been reported to emerge in the commu-
nity setting. We describe the investigation and control of a community-acquired outbreak of MRSA skin
infections in a closed community of institutionalized adults with developmental disabilities. In a 9-month
period in 1997, 20 (71%) of 28 residents had 73 infectious episodes. Of the cultures, 60% and 32%
obtained from residents and personnel, respectively, grew S. aureus; 96% and 27% were MRSA. All iso-
lates were genetically related by pulsed-field gel electrophoresis and belonged to a phage type not previ-
ously described in the region. No known risk factors for MRSA acquisition were found. However, 58
antibiotic courses had been administered to 16 residents during the preceding 9 months. Infection control
measures, antibiotic restriction, and appropriate therapy resulted in successful termination of this out-
break. Selective antibiotic pressure may result in the emergence, persistence, and dissemination of MRSA
strains, causing prolonged disease.
ethicillin-resistant  Staphylococcus aureus (MRSA)
poses a therapeutic challenge in acute-care settings (1–
4), as well as long-term skilled-nursing facilities (5–8).
Recently, MRSA has also been detected in the community
more often. The terms and definitions related to community-
acquired MRSA remain controversial, and the “community” as
a milieu for MRSA acquisition cannot be implicated with a
high degree of certainty. Most studies have defined community
acquisition as growth within 48–72 hours after hospital admis-
sion (9–11), which does not rule out nosocomial acquisition.
Patients thought to have acquired MRSA in the community
carry risk factors implicated in nosocomial acquisition (12–
16). 
Outbreaks of community-acquired MRSA infection are
extremely rare (17–19). During 1997, we investigated an out-
break of skin and soft-tissue infection involving MRSA in a
closed community of institutionalized adults with develop-
mental disabilities. MRSA emerged and disseminated in this
setting as a result of an extreme selective pressure exacerbated
by heavy and continuous use of ineffective antimicrobial
drugs. That such selective pressure was sufficient to promote
MRSA emergence in the community underlines the threat




The outbreak occurred in a facility for persons with devel-
opmental disabilities, located in the Negev, southern Israel.
The facility consists of 283 residents living in nine buildings
and confined to the institution. Residents are independent with
regard to activities of daily living, with minimal contact
between residents of different buildings. Staff consists of 120
personnel who work exclusively in the institution and are
assigned to specific buildings. Medical attention is provided
by an institutional clinic. The outbreak involved a single build-
ing (number 15) inhabited by 28 residents and attended by 34
personnel. 
Epidemiologic Investigation
The outbreak investigation began in December 1997,
according to the principles of the Declaration of Helsinki.
Informed consent was obtained from personnel, and consent
for including residents was obtained from legal guardians and
the Ministry of Health.
Information was reviewed regarding possible host risk fac-
tors (20), including age, sex, diabetes mellitus, malignancy,
coronary disease, chronic lung, hepatic or renal diseases, neph-
rotic syndrome, congestive heart failure, obesity, debilitating
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conditions, and pressure sores, as well as therapeutic risk fac-
tors such as urinary catheters, nasogastric tubes, and other ind-
welling devices, steroid treatment and antibiotic therapy
prescribed during 12 months preceding the outbreak. Admis-
sions to any acute-care facility during the previous 5 years
were recorded.
To confirm clustering and identify common sources of
transmission, all 28 residents from building 15 were screened
for both methicillin-sensitive S. aureus (MSSA) and MRSA
carriage in both anterior nares, perineum, and secreting lesions.
Nare and exudate cultures were obtained from all personnel in
contact with the residents (34 persons). Additionally, nares cul-
tures were randomly obtained from one-fifth of all residents (50
persons) residing in other buildings at the institution. 
Laboratory Investigation
Cultures were obtained by rotating a moistened swab in
both nares, perineum area, and secreting lesions and were pro-
cessed at the Clinical Microbiology Laboratory of the Soroka
University Medical Center. Identification of S. aureus was per-
formed by routine methods. Methicillin resistance was deter-
mined by using a 1-µg oxacillin disk. Susceptibility to
erythromycin, clindamycin, cefuroxime, ceftriaxone, ciprof-
loxacin, gentamicin, fusidic acid, and vancomycin was deter-
mined by using the disc-diffusion method. Mupirocin
resistance (MIC>256 mg/L) was determined by E-test (AB
Biodisk, Solna, Sweden). 
Bacteriophage typing at routine test dilutions was per-
formed at a national reference laboratory, Rabin Medical Cen-
ter, Petah-Tikva, Israel. Methicillin resistance was confirmed
by polymerase chain reaction (PCR) for the mecA gene (21).
Pulsed-field gel DNA electrophoresis (PFGE) for the determi-
nation of genetic relatedness was generated by digestion with
the restriction endonuclease SmaI as described elsewhere (22),
and the banding pattern was interpreted according to current
consensus (23).
Intervention
Management of the outbreak was carried out by the four-
phase approach of Wenzel et al. (24), with modifications
related to the setting under investigation. Basic epidemiologic
measures, infection control measures, and isolation precau-
tions were instituted, including glove use during personnel-
resident contact, hand washing with 4% chlorhexidine after
glove removal, reserving personal washcloths and towels for
each resident, bathing daily with 4% chlorhexidine-containing
soap, and changing towels, clothing, and bed sheets daily.
Draining lesions were covered at all times with sterile dress-
ings, which were promptly discarded after removal.
Treatment to eliminate nasal carriage in culture-positive
persons was given after randomization, by using either intrana-
sal mupirocin calcium 2% ointment (Bactroban, Glaxo Smith-
Kline, Philadelphia, PA) or sodium fusidate 2% ointment
(Fucidin, Leo Pharmaceutical, Ballerup, Denmark), twice a
day for a week. Spontaneous or surgically drained lesions were
treated with the same topical antibiotic used intranasally. Sys-
temic therapy with oral fusidic acid 500 mg twice a day (Fuci-
din, Leo Pharmaceutical) was reserved only for lesions
surrounded by cellulitis, located around the mid-face, or in
presence of systemic symptoms or signs. To limit antibiotic
use, therapy other than the above was not allowed. This phase
was supervised by infectious-disease specialists. Thereafter,
infection control was supervised weekly by an infection
control nurse and every 3 weeks by an infectious-disease
specialist.
In the implicated building, follow-up cultures were
obtained from all residents and personnel 1 week as well as 1
month after intervention. After 2 additional weeks, repeat cul-
tures were obtained only from those with previous positive
culture. Two years later, in March 2000, nares cultures were
obtained from of all residents in order to assess the prevalence
of persistent carriage. 
Statistical Analysis
Statistical analysis was performed with the Epi-Info soft-
ware (Version 6.03; 1996, Centers for Disease Control and
Prevention, Atlanta, GA), using the chi-square and Fisher’s




During mid-1997, an increasing number of skin and soft-
tissue infections in residents of a single building were recog-
nized by the staff. No cases were diagnosed in residents in
other buildings or the remaining staff. The initial case involved
an uncomplicated furuncle in a patient with dermatitis. From
March 1, 1997, to December 31, 1997, 60 patient visits related
to skin, soft-tissue, ear, and eye infections were recorded; 14
(23%) of these visits required surgical intervention by a local
physician, but no culture material was available for analysis.
No patients required referral or hospital admission.
In all, 73 infectious episodes were recorded in 20 of 28 res-
idents in the implicated building, including 43 (59%) skin
abscesses, 20 (27%) furuncles, 8 (11%) purulent conjunctivi-
tis, and 2 (3%) external otitis. A mean of seven episodes per
month (median 7, range 4–14) peaked in December 1997. The
implicated organism was MRSA.
Epidemiologic Survey
The median age of residents in building 15 was 32 years
(range 18–45 years), and all residents were male. The mean
stay at the institution was 16.3 years ± 6.6 years. We could not
identify any known risk factor for MRSA carriage or infection.
No residents had been admitted to acute-care hospitals within
the 5 years preceding the outbreak, and no contact with known
carriers was established. However, 58 courses of oral antibiot-
ics, including amoxicillin, amoxicillin-clavulanate, penicillin,
cefuroxime-axetil, cloxacillin, erythromycin, ciprofloxacin,RESEARCH
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and trimethoprim-sulfamethoxazole, were administered to 16
of 20 (80%) infected residents during a 9-month period, for a
total of 572 antibiotic-days (Figure 1). Excess antibiotic con-
sumption was not observed in other buildings.
Bacteriologic Survey
The first survey was carried out in December 1997 and
included 83 cultures, of which 48 were obtained from 28 resi-
dents, consisting of 28 (58%) nasal, 10 (21%) perineal, and 10
(21%) exudate cultures. Thirty-four nasal and one exudate cul-
tures were obtained from personnel. Forty of 83 were positive,
48% grew MRSA or MSSA, for a positive culture rate of 29
(60%) of 48 in residents and 11 (32%) of 35 in personnel. Sev-
enteen (61%) of 28 and 10 (29%) of 34, residents and person-
nel, respectively, were nasal carriers of S. aureus; 16 (95%)
and 2 (20%) of the isolates were MRSA. Eighteen (29%) of 62
nasal, 2 (20%) of 10 perineal, and all 11 exudate cultures
(including 1 from staff) grew MRSA (a total of 31 isolates). 
All 31 MRSA isolates were susceptible to ciprofloxacin,
gentamicin, fusidic acid, and vancomycin, but only 14 (45%)
were susceptible to clindamycin and erythromycin. Typing
showed that all MRSA isolates belonged to phage-type 29/52/
54/95/47/HK2 [52A/79/75/92], an unusual type that had not
been isolated before from any patient either in the community
or the acute-care setting in southern Israel. All MRSA isolates
from both carriers and infected persons yielded an indistin-
guishable PFGE pattern, except for one isolate that yielded a
closely related pattern (one band difference) and was thought
to belong to the outbreak strain (Figure 2). 
In residents, the 17 nasal carriers had 57 episodes of skin
infections during 1997 compared with 16 episodes in 11 non-
carriers (p<0.01). At this point, infection control measures
were enforced and carriers were randomized to receive intra-
nasal mupirocin (11 cases) or sodium fusidate (14 cases). The
same agent was applied topically after drainage.
Postintervention Survey
The nasal carriage eradication rate was 11 (100%) of 11 for
mupirocin and 9 (64%) of 14 for sodium fusidate (p=0.08).
The five carriers in whom fusidic acid failed were retreated 2
weeks later with mupirocin and complete eradication was
achieved.
In January 1998, a third survey was carried out, including
72 cultures (62 persons), 8 (11%) of which were positive. Of
the residents’ cultures, five (two nasal and three exudate cul-
tures) grew MRSA. Three nasal cultures obtained from per-
sonnel grew MSSA. One-fifth of the remaining residents and
personnel were screened (80 persons), and none were found to
be MRSA carriers. No infections were recorded outside build-
ing 15 throughout the study period. 
Eleven new episodes of furuncles yielding mupirocin-sensi-
tive MRSA were recognized postintervention, involving five
residents and one personnel. Six responded to topical mupiro-
cin, while systemic fusidic acid was clinically indicated in five
(27 antibiotic days). Since March 1998, no additional episodes
were diagnosed in 2 years of follow-up. In March 2000, the
nasal culture survey was repeated in the 28 residents. Two (7%)
of 28 cultures grew S. aureus, MSSA in one resident and MSSA
together with MRSA in another. The latter patient had recurrent
colonization for 2 years despite repeated eradication efforts,
even while the rest of the residents were culture negative.
Discussion
MRSA is an important pathogen in both acute-care and
long-term care facilities (1–7). The complex interaction
between patients admitted to chronic- and acute-care facilities
is well-known, and the resulting “import” and “export” of
MRSA is of great concern (25), making MRSA outbreaks
problematic. Defining community-acquired MRSA with accu-
racy is difficult since widely used criteria seem to reflect
“community existence” rather than “community acquisition.”
Persistent nasal carriage, which may involve up to 35% of car-
riers (26,27), can further complicate any attempt to determine
the exact time of acquisition. 
We describe an outbreak of community-acquired MRSA
infections in which the only identified risk factor was a history
Figure 1. Systemic antibiotic use agents administered to infected resi-
dents in Building 15 between March and December 1997. Shaded bars
represent beta-lactam agents.
Figure 2. Pulse-field gel electrophoresis of study isolates obtained dur-
ing the first survey on December 1997 from residents and staff.
Lambda ladder and the DNA of the reference Streptococcus pneumo-
niae strain R6, digested by SmaI, were used as molecular weight mark-
ers. The gel includes 25 representative MRSA isolates. All isolates but
one show an indistinguishable banding pattern, thus representing the
outbreak strain. Isolate number 23 shows a closely related pattern (one
band difference) and is considered to belong to the outbreak strain.Emerging Infectious Diseases  •  Vol. 8, No. 9, September 2002 969
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of heavy exposure to multiple antibiotics, especially beta-lac-
tams, over a relatively short period of time in a population liv-
ing under closed conditions. The first stage leading to
selection of MRSA within MSSA isolates in hospitalized
patients is antibiotic treatment (4,28). Such selective pressure
permits the growth of a multiresistant bacterial population
within a susceptible one, a process that may take <48 hours in
approximately 15% of MSSA nasal carriers (4). 
Thus, massive antibiotic pressure appears to be an impor-
tant mechanism for the selection of community-acquired
MRSA and its subsequent dissemination when favorable envi-
ronmental conditions exist, as in the outbreak presented here.
Although introduction of an MRSA strain from outside the
facility cannot be absolutely ruled out, this possibility is less
favorable owing to the epidemiologic features of the popula-
tion, lack of contact with known carriers or admission to
acute-care facilities, lack of risk factors except antibiotic ther-
apy, and the uniqueness of the outbreak strain’s phage type in
our country. MRSA emergence in the institution was possible
given that contemporary epidemic MRSA clones are actually
descendents of old MSSA isolates that had received the mecA
element and that the evolution of MRSA from of MSSA lin-
eages appears to coincide with selective antibiotic pressure
after the introduction of new antibiotics (29).
Skin and soft tissue infections are by far the commonest
infections caused by S. aureus, and similar to other community-
acquired MRSA outbreaks (17–19), recurrent abscesses, or
furuncles, or both were the predominant infection in our study.
A high prevalence of skin infection has been shown to be a risk
factor for persistent nasal carriage of MRSA, augmenting per-
son-to-person transmission (23). Moreover, patients with
pathologic skin conditions have a higher risk not only of
acquiring skin infections but also of dispersion of infecting
strains (27,30,31). Failure to consider MRSA as a cause of such
infections may lead to delayed diagnosis and inappropriate
therapy, permitting a cycle of disease progression and wide-
spread transmission. Fortunately, no invasive infections
occurred as might have been expected in MRSA-colonized
patients in nosocomial settings (32). Propagation of the out-
break could be explained by the close and continued physical
contact between residents and staff, facilitating transmission,
with the high rate of nasal colonization in residents serving as
an independent risk factor for MRSA infection (33–35). 
Elimination of carriage was achieved by intranasal antibi-
otics (either mupirocin or fusidic acid); the aim was to control
the outbreak and prevent recurrence. We also treated the great
majority of infections topically, in addition to bathing with
chlorhexidine and appropriate drainage with the intention of
maximally reducing systemic antibiotic use. 
While mupirocin is a well-accepted eradication regimen
(24), the possible emergence of mupirocin resistance during
therapy (especially with skin application) should be consid-
ered. Fusidic acid, widely used in Israel, has been shown to be
a convenient and risk-free method for eradication of nasal S.
aureus carriage (36), but currently no comparative data evalu-
ate both agents. In our population, only five cases required
systemic therapy, according to study indications, and mupiro-
cin resistance was not detected during follow-up. However,
persistent nasal MRSA carriage, 2 years after the onset of the
outbreak, demonstrates a continued potential threat for both
the reemergence of MRSA in the institution and perhaps, dis-
semination to the community.
Our essential goal was to achieve maximal infection con-
trol while maintaining selective pressure at the minimum. Crit-
ical factors, which are difficult to achieve in nosocomial
settings, allowed us to achieve nearly total eradication of
MRSA: 1) only one resident appeared to be a persistent nasal
MRSA carrier; 2) all residents were exposed during a specific
time frame without mingling between newly admitted or dis-
charged residents; 3) enforcement of strict environmental
cleansing and infection control measures; and 4) selective anti-
biotic pressure owing to minimal use of systemic agents (only
5 courses).
In conclusion, massive, and perhaps unjustified, systemic
antibiotic use in communities, particularly those involving
close interaction between members, may permit the emergence
of multiresistant bacteria such as MRSA, with a high risk for
disease. Implementation of antibiotic control strategies is cru-
cial to prevent the dissemination of MRSA in the community
as a whole.
Dr. Borer is a specialist in internal medicine, infectious diseases,
and hospital epidemiology and head of the Infection Control Team at
the Soroka University Medical Center. His research focuses on infec-
tion control and hospital epidemiology.
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